** Shares of Ionis Pharma and Alnylam Pharma fall after Pfizer's drug to treat transthyretin(TTR) cardiomyopathy, a rare and fatal disease linked to heartfailure, succeeds in late-stage study** ALNY shares slumped 19.09 pct to $97.55; IONS sharesdipped 6.03 pct to $41.42
** ALNY and IONS are developing separate treatments forhereditary TTR amyloidosis ** TTR cardiomyopathy is a condition that results fromdeposits of transthyretin protein in the heart, which leads toeventual heart failure** Stifel analyst Stephen Wiley said data could be negativefor Alnylam and Ionis** Some investors could look at Pfizer's data as providingvalidation for both companies' drugs, Wiley said, adding that hebelieved the data could potentially complicate product labelingfor both drugs** Needham analysts expect Pfizer's drug could be approvedin U.S. in second half of 2019** Up to Thursday's close, ALNY fell 6.3 pct and IONSdropped 12.4 pct this year (Reporting by Akankshita Mukhopadhyay in Bengaluru) Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.